<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; challenged</title>
	<atom:link href="http://www.tapanray.in/tag/challenged/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Navigating Potential US Tariffs: Challenges and AI-Driven Opportunities for Indian Pharma</title>
		<link>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma</link>
		<comments>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 09 Aug 2025 08:09:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[challenged]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10955</guid>
		<description><![CDATA[India’s pharmaceutical industry, reportedly supplying 47% of US generic drugs and exporting $27.9 billion in FY24, faces the threat of 10-25% US tariffs under a potential Trump policy. Major players like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Aurobindo, reportedly &#8230; <a href="http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
